Learning Objectives:
1) Describe the pharmacologic characteristics of common medications indicated for the treatment of type 2 diabetes mellitus, which have been FDA-approved or used off-label for the treatment of heart failure, CKD, obesity, MASH/MASLD, & OSA.
2) Discuss key takeaways from relevant primary literature that support the use of common medications indicated for the treatment of type 2 diabetes mellitus, in the FDA-approved or off-label treatment of heart failure, CKD, obesity, MASH/MASLD, & OSA.
3) Utilize an evidence-based medicine approach in a patient case to select an appropriate therapy regimen to improve patient health outcomes & quality of life.
Accreditation Statement for DOCME programs:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Mississippi Osteopathic Medical Association (MOMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
Disclosure:
Mr. Joseph Nosser, PharmD has no actual or potential conflict of interest in relation to this program or presentation.
Grievance Statement:
All grievances may be directed to MOMA's Executive Director at info@moma-net.org. All grievances will receive an initial response within 30 days of receipt. If the participant does not receive a satisfactory response, they can submit a complaint to the Bureau of Osteopathic Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.